Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Hematology/Oncology

Anti-EGFR Therapy: Incidence, Pathology and Management of Associated Side Effects

This month, Sunil Babu, M.D., Michael Liu, M.D., and Robert G. Lerner, M.D., discuss

CME credit is no longer available for this conference.

Course Authors

Sunil Babu, M.D., Michael Liu, M.D., and Robert G. Lerner, M.D.

Dr. Babu is Fellow in Hematology/Oncology at New York Medical College/Westchester Medical Center, Valhalla, NY, and Dr. Liu is Resident in Internal Medicine at Cabrini Medical Center, New York, NY.

Within the past 12 months, Dr.Babu and Dr. Liu report no commercial conflicts of interest. Dr. Lerner reports research support from Boehringer-Ingelheim, Sanofi-Aventis and Bayer and is on the Speakers Bureau for Sanofi-Aventis, GlaxoSmithKline and Eisai.

Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose.

This activity is made possible by an unrestricted educational grant from Bristol Myers Squibb

Release Date: 06/05/2007

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Describe the common side effects associated with EGFR inhibition

  • Discuss the correlation between dermatologic side effects of EGFR inhibition and response to therapy

  • Discuss the possible mechanisms of dermatologic side effects of EGFR inhibitor therapy

  • Discuss the common principles of management of dermatologic and non-dermatologic side effects.

 

TERMS AND CONDITIONS

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms.

Courses You Might Like

Alcohol Abuse and Cancer

poses unique challenges for clinicians. This Cyberounds® will focus on the epidemiology, pathophysiology, clinical implications and management strategies for the comorbidity of AUD and cancer. The goal is to provide a comprehensive, clinically oriented overview that highlights the intricate relationship between these two conditions and the implications for patient care. …
Authors: Danilo De Gregorio, PharmD, Ph.D.
View Course
More

AML2

View Course
More

Emerging Treatments In Acute Myeloid Leukemia (AML)

Several investigational agents offer hope to patients with AML.
Authors: Mary-Elizabeth M. Percival, M.D., M.S. and Roland B. Walter, M.D., Ph.D., M.S.
View Course
More

Pro-State Challenge 2

View Course
More

Unexplained Bleeding in Hospitalized Patients

While some disorders are more readily apparent than others, not all bleeding is straightforward or has a readily identifiable cause.
Authors: Meera B. Chitlur, M.D.
View Course
More

Lung Cancer Chemoprevention

Despite advances in lung cancer chemotherapy, there is a pressing need for effective lung cancer chemoprevention beyond smoking cessation.
Authors: Robert L. Keith, M.D.
View Course
More